Study of the Cost Effectiveness of Therapy in Hypertention Patients in Hospital


  • Richa Yuswantina Ngudi Waluyo University
  • Niken Dyahariesti
  • Diastri Dwi Ambarwati



Hypertension is where the blood pressure is > 140 mmHg and > 90 mmHg. Combination therapy is needed if a single antihypertensive has not been able to control the desired blood pressure target while the cost of treatment is increasing from time to time. The purpose of this study was to determine the cost-effective combination therapy for antihypertensive drugs in hypertensive patients in an inpatient setting. This study is a descriptive study with a pharmacoeconomic analysis approach using the Cost Effectiveness Analysis (CEA) method which was carried out retrospectively. Data were collected using the Total Sampling technique with 93 patients which were then analyzed to determine the cost-effective therapy based on ACER and ICER. The results showed that hypertension was mostly experienced by patients aged 50-60 years, male sex was more than female. HT stage 2 is often experienced by patients. Type II DM is the most common comorbidity. The lowest ACER value is Rp. 65.195.77. The lowest ICER value is Rp. 7.047.2551 when compared with standard therapy, namely CCB + ACEI. The combinations used in the inpatient unit include two combinations of 42 patients (45.16%) three combinations of 37 patients (39.78%), four combinations 6 (6.45%) five combinations of 8 patients (8.6%). The lowest average direct medical cost is the combination of ACEI antihypertensive + Diuretic + -Blocker Rp. 2.765.262. The cost effective therapy based on ACER and ICER values is a combination of Diuretics + CCB + ACEI + Blockers with an ACER value of Rp. 65,195.77 and also dominant.



Download data is not yet available.


Indonesia M of H of the R of. Technical Guidelines for Finding and Management of Hypertension. 2013.

Durojaiye OC, Bell H, Andrews D, Ntziora F, Cartwright K. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018 Jan;51(1):26–32.

Mpila, D. A., & Lolo WA. The relationship between the rationale of the use of antihypertensive drugs on the clinical outcome of hypertensive patients at the Manado Clinic. J Pharmacon. 2022;

Ostermann JK, Witt CM, Reinhold T. A retrospective cost-analysis of additional homeopathic treatment in Germany: Long-term economic outcomes. PLoS One. 2017;12(9):e0182897.

Maulidina, F., Harmani, N. & SI. Factors Associated with the Incidence of Hypertension in the Working Area of the Jati Luhur Health Center Bekasi in 2018. 2019.

Page TF, Pelham WE 3rd, Fabiano GA, Greiner AR, Gnagy EM, Hart KC, et al. Comparative Cost Analysis of Sequential, Adaptive, Behavioral, Pharmacological, and Combined Treatments for Childhood ADHD. J Clin Child Adolesc Psychol. 2016;45(4):416–27.

Andayani TM. Pharmacoeconomics, Principles and Methodology. Yogyakarta: Bursa Ilmu; 2013.

Zulfah M. Cost Effectiveness Analysis of Combination Antihypertensive Drugs in Inpatients at Dr. Hospital. Soekardjo Tasikmalaya. J Pharmacopolium. 2019;

Lutfiyati, H., Yuliastuti, F., & Khotimah A. Pattern of Hypertension Treatment in Elderly Patients at the Windusari Health Center, Magelang Regency. J Farm Sains dan Prakt. 2017;

Hubner C, Hubner NO, Muhr M, Claus F, Leesch H, Kramer A, et al. Cost analysis of hospitalized Clostridium difficile-associated diarrhea (CDAD). GMS Hyg Infect Control. 2015;10:Doc13.


PlumX Metrics



How to Cite

Yuswantina, R., Dyahariesti, N., & Ambarwati, D. D. (2023). Study of the Cost Effectiveness of Therapy in Hypertention Patients in Hospital. Jurnal Midpro, 15(1), 62–68.

Most read articles by the same author(s)